Environmental Economics

Dose-Response Assessment in Regulatory Risk Analysis

This paper discusses the current practices and assumptions used by researchers to assess dose-response for different human chronic toxicity endpoints as part of the Rebuttable Presumption Against Registration (RPAR) risk assessment process. The categories discussed are: 1) endpoints other than cancer and mutation, 2) oncogenic endpoints, and 3) mutation. Problems with using experimental data to determine the "no observed effect level" (NOELs) for noncarcinogenic endpoints are discussed. Five different modeling procedures for carcinogenic effects (Mantel-Bryan procedure, one-hit model, linearized multistage model, gamma multi-hit model, and multistage model) are also discussed. The paper concludes with a general discussion of the problems with the dose-response assessment methodologies for cancer and non-genotoxic endpoints.

  • Keywords

    1. Benefits Analysis
    1. Benefits Analysis - Quantification without Monetization
    Environmental Media:
    f. Multimedia
    Bogen, Kenneth T.
    EPA Project Officer/ Manager:
    Geographic Area:
    Study Purpose:
    Methodology Development & Evaluation
    Inventory Record #: EE-0103
  • Report Details
    Number of Pages:
  • How to Obtain Report

    Download report now, Order a copy of report

    Use link(s) to download or view the report

    Date Linked: 08/25/2017